ATE427121T1 - Gegen gewebefaktor gerichtete antikírper als antikoagulantien - Google Patents

Gegen gewebefaktor gerichtete antikírper als antikoagulantien

Info

Publication number
ATE427121T1
ATE427121T1 AT03721974T AT03721974T ATE427121T1 AT E427121 T1 ATE427121 T1 AT E427121T1 AT 03721974 T AT03721974 T AT 03721974T AT 03721974 T AT03721974 T AT 03721974T AT E427121 T1 ATE427121 T1 AT E427121T1
Authority
AT
Austria
Prior art keywords
anticoagulants
directed against
antibodies directed
tissue factor
against tissue
Prior art date
Application number
AT03721974T
Other languages
English (en)
Inventor
David Light
Kirk Mclean
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427121(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE427121T1 publication Critical patent/ATE427121T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT03721974T 2002-05-01 2003-04-30 Gegen gewebefaktor gerichtete antikírper als antikoagulantien ATE427121T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01

Publications (1)

Publication Number Publication Date
ATE427121T1 true ATE427121T1 (de) 2009-04-15

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03721974T ATE427121T1 (de) 2002-05-01 2003-04-30 Gegen gewebefaktor gerichtete antikírper als antikoagulantien
AT03721975T ATE484524T1 (de) 2002-05-01 2003-04-30 Neue gegen den gewebefaktor gerichtete thrombomodulin-fusionsproteine als antikoagulantien

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03721975T ATE484524T1 (de) 2002-05-01 2003-04-30 Neue gegen den gewebefaktor gerichtete thrombomodulin-fusionsproteine als antikoagulantien

Country Status (29)

Country Link
US (3) US7250168B2 (de)
EP (2) EP1503785B1 (de)
JP (2) JP4460443B2 (de)
KR (2) KR101013697B1 (de)
CN (2) CN100563709C (de)
AR (1) AR039515A1 (de)
AT (2) ATE427121T1 (de)
AU (2) AU2003225255B2 (de)
BR (2) BR0304659A (de)
CA (2) CA2483910A1 (de)
CR (1) CR7584A (de)
DE (2) DE60326970D1 (de)
DK (2) DK1503785T3 (de)
EC (2) ECSP045468A (de)
ES (2) ES2354419T3 (de)
HK (1) HK1080372A1 (de)
IL (3) IL164733A0 (de)
MX (2) MXPA04010795A (de)
NO (2) NO20035848L (de)
NZ (2) NZ536243A (de)
PE (1) PE20040597A1 (de)
PL (2) PL210582B1 (de)
PT (2) PT1503785E (de)
RS (2) RS104504A (de)
RU (2) RU2345789C2 (de)
TW (1) TWI343388B (de)
UA (2) UA85996C2 (de)
WO (2) WO2003092602A2 (de)
ZA (2) ZA200409692B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (de) 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Neues Hämopoietin Receptorprotein, NR10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7312325B2 (en) 2000-09-26 2007-12-25 Duke University RNA aptamers and methods for identifying the same
HK1080372A1 (zh) * 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US7579000B2 (en) * 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
EP1539235A2 (de) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Spezifisch an reg iv bindende antikörper
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
EP2460811A1 (de) 2004-04-22 2012-06-06 Regado Biosciences, Inc. Verbesserte Modulatoren von Gerinnungsfaktoren
CA2609262A1 (en) 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. Anti-cd14 antibody fusion protein
US20090130104A1 (en) * 2005-10-05 2009-05-21 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
ES2353084T3 (es) * 2006-04-07 2011-02-25 Novo Nordisk Health Care Ag Complejo covalente de factor vii y factor tisular.
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
RU2433829C2 (ru) * 2006-10-06 2011-11-20 Асахи Касеи Фарма Корпорейшн Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании
WO2008121814A1 (en) * 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
CN101855243A (zh) * 2007-09-20 2010-10-06 伯拉考成像股份公司 用于制备新的寡克隆抗体的方法
CA2708065C (en) * 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
WO2009086552A1 (en) * 2008-01-02 2009-07-09 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (de) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antikörper, die speziell im Koronarplaque aktiv sind und Verfahren zur ihrer Identifizierung
EP2470201A4 (de) * 2009-08-28 2013-01-30 Bayer Healthcare Llc Kofaktoren zur faktor-vii-thrombinaktivierung und anwendungen davon
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
CN107188970A (zh) 2010-06-04 2017-09-22 株式会社蒂奥姆生物 具有因子vii活性的融合蛋白质
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
CL2011001887A1 (es) * 2010-08-05 2012-02-03 Council Scient Ind Res Construcciones de proteinas quimericas que poseen propiedades anticoagulantes y tromboliticas; secuencia de acido nucleico que las codifica; vector; celula huesped; metodo de preparacion; formulacion farmaceutica que las comprende; y su uso para inhibir la trombina.
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
US10954502B2 (en) * 2015-04-28 2021-03-23 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein C activators
US11085031B2 (en) 2016-04-28 2021-08-10 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
US11104718B2 (en) * 2016-11-16 2021-08-31 Bayer Healthcare Llc Red blood cell targeted factor VIII and method of using the same
BR102017005783A2 (pt) 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
EP3861127A1 (de) * 2018-10-04 2021-08-11 Thrombosis and Coagulation AB Verfahren zur bestimmung des protein-s-spiegels
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MX2022005654A (es) 2019-11-20 2022-06-22 Chugai Pharmaceutical Co Ltd Preparacion que contiene anticuerpo.
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
WO1990010081A1 (en) * 1989-02-17 1990-09-07 Codon Soluble analogs of thrombomodulin
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
WO2001070984A2 (en) * 2000-03-16 2001-09-27 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003201159A1 (en) 2002-01-08 2003-07-24 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
HK1080372A1 (zh) 2002-05-01 2006-04-28 Schering Aktiengesellschaft 作为抗凝剂的新型组织因子目标抗体
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
US7622457B2 (en) 2009-11-24
KR20050045945A (ko) 2005-05-17
JP4460443B2 (ja) 2010-05-12
BR0304659A (pt) 2004-09-21
MXPA04010851A (es) 2005-02-14
EP1549341A4 (de) 2006-10-18
JP4567437B2 (ja) 2010-10-20
NO20035848L (no) 2004-02-27
UA81114C2 (en) 2007-12-10
MXPA04010795A (es) 2005-03-07
CA2483910A1 (en) 2003-11-13
EP1503785A2 (de) 2005-02-09
EP1549341A2 (de) 2005-07-06
RS104504A (sr) 2007-02-05
EP1549341B1 (de) 2009-04-01
WO2003092602A3 (en) 2004-08-26
KR20050045944A (ko) 2005-05-17
WO2003093422A3 (en) 2004-07-15
PE20040597A1 (es) 2004-10-06
EP1503785A4 (de) 2007-02-14
RU2320366C2 (ru) 2008-03-27
KR101013697B1 (ko) 2011-02-10
RS102404A (sr) 2006-12-15
CN100412090C (zh) 2008-08-20
ATE484524T1 (de) 2010-10-15
DK1549341T3 (da) 2009-07-06
PL210582B1 (pl) 2012-02-29
BR0304660A (pt) 2005-06-07
CN1665534A (zh) 2005-09-07
JP2005532045A (ja) 2005-10-27
HK1080372A1 (zh) 2006-04-28
IL164733A0 (en) 2005-12-18
ES2323056T3 (es) 2009-07-06
PL373960A1 (en) 2005-09-19
TW200307043A (en) 2003-12-01
DE60326970D1 (de) 2009-05-14
NO20035849L (no) 2004-02-27
TWI343388B (en) 2011-06-11
PT1549341E (pt) 2009-05-29
ECSP045468A (es) 2005-01-28
RU2345789C2 (ru) 2009-02-10
US7250168B2 (en) 2007-07-31
AU2003225255A1 (en) 2003-11-17
ES2354419T3 (es) 2011-03-14
US20080019985A1 (en) 2008-01-24
WO2003093422A2 (en) 2003-11-13
US20080020965A1 (en) 2008-01-24
AU2003225256B2 (en) 2009-06-04
RU2004135308A (ru) 2005-08-10
ZA200409692B (en) 2006-07-26
IL164733A (en) 2011-05-31
CR7584A (es) 2006-05-30
DE60334538D1 (de) 2010-11-25
NZ536243A (en) 2006-06-30
US7622122B2 (en) 2009-11-24
US20040063632A1 (en) 2004-04-01
ZA200409694B (en) 2006-02-22
UA85996C2 (ru) 2009-03-25
ECSP045467A (es) 2005-01-28
PL373945A1 (en) 2005-09-19
PT1503785E (pt) 2011-01-17
CN1665526A (zh) 2005-09-07
IL164732A0 (en) 2005-12-18
JP2005538046A (ja) 2005-12-15
WO2003092602A2 (en) 2003-11-13
KR101080587B1 (ko) 2011-11-04
CA2483909A1 (en) 2003-11-13
CN100563709C (zh) 2009-12-02
NZ536242A (en) 2006-04-28
DK1503785T3 (da) 2011-02-07
AR039515A1 (es) 2005-02-23
EP1503785B1 (de) 2010-10-13
RU2004135306A (ru) 2005-07-10
AU2003225255B2 (en) 2008-07-31
AU2003225256A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
ATE427121T1 (de) Gegen gewebefaktor gerichtete antikírper als antikoagulantien
DE60330694D1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE515515T1 (de) Immunglobuline gegen menschlisches osm
EP1596190A4 (de) Sensor
DE602004031798D1 (de) Verbinder
DE602004022898D1 (de) Verbinder
PT1484995E (pt) Guarda-chuva inclinavel
DE60317391D1 (de) Verbinder
DE602004019448D1 (de) Aramidfibrillen
EP1663544A4 (de) Verbundlenkungszahnstange
DE60208885D1 (de) Verbinder
EP1664117A4 (de) Immunogen
DE50302584D1 (de) Stereomikroskop
SE0402458L (sv) Igensättningsmotverkande behandlingar
DE50302514D1 (de) Stereomikroskop
DE602004004295D1 (de) 6-ä(substituiertes)phenylütriazolopyrimidine als antikrebsmittel
DE10301279B8 (de) Verbinder
DE50301609D1 (de) Flanscheinheit
FI20021934A0 (fi) Liittopalkki
DE502004005544D1 (de) Mikrodosiereinrichtung
ATE501123T1 (de) Sulfonylaminopyrazole als pestizide
EP1618261A4 (de) Verbundträger
FR2840006B1 (fr) Construction demontable
DE602004029860D1 (de) Verbinder
FR2849861B1 (fr) Detecteur biologique

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1549341

Country of ref document: EP